<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36208052</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Mexiletine in spinal and bulbar muscular atrophy: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>1702</StartPage><EndPage>1714</EndPage><MedlinePgn>1702-1714</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51667</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Patients with spinal and bulbar muscular atrophy (SBMA) often experience muscular weakness under cold exposure.</AbstractText><AbstractText Label="METHODS">In our previously conducted observational study, we assessed nerve conduction and grip strength to examine the effect of cold exposure on motor function, based on which we conducted a randomized controlled trial to evaluate the efficacy and safety of mexiletine hydrochloride in SBMA (MEXPRESS).</AbstractText><AbstractText Label="RESULTS">In the observational study, 51 consecutive patients with SBMA and 18 healthy controls (HCs) were enrolled. Of the patients with SBMA, 88.0% experienced cold paresis. Patients with SBMA exhibited greater prolongation of ulnar nerve distal latency under cold (SBMA, 5.6&#x2009;&#xb1;&#x2009;1.1&#x2009;msec; HC, 4.3&#x2009;&#xb1;&#x2009;0.6&#x2009;msec; p&#x2009;&lt;0.001); the change in the distal latencies between room temperature and cold exposure conditions correlated with the change in grip power. In the MEXPRESS trial, 20 participants took mexiletine or lactose, three times a day for 4&#x2009;weeks with a crossover design. There was no difference in distal latencies at room temperature and under cold exposure between mexiletine and placebo groups as the primary endpoint. However, tongue pressure and 10-sec grip and release test under cold exposure were improved in the mexiletine group. There were no serious adverse events throughout the study period.</AbstractText><AbstractText Label="INTERPRETATION">Cold paresis is common and associated with prolongation of distal latency in SBMA. The results of the phase II clinical trial revealed that mexiletine showed short-term safety, but it did not restore cold exposure-induced prolongation of distal latency.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Shinichiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hashizume</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hijikata</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inagaki</LastName><ForeName>Tomonori</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ito</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kishimoto</LastName><ForeName>Yoshiyuki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Fumie</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirakawa</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Shinobu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakamura</LastName><ForeName>Tomohiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsuno</LastName><ForeName>Masahisa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9453-9311</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Research Education, Nagoya University Graduate School of Medicine, Nagoya, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>1U511HHV4Z</RegistryNumber><NameOfSubstance UI="D008801">Mexiletine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008801" MajorTopicYN="Y">Mexiletine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="Y">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011312" MajorTopicYN="N">Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014059" MajorTopicYN="N">Tongue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018908" MajorTopicYN="N">Muscle Weakness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010291" MajorTopicYN="N">Paresis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no financial or non&#x2010;financial conflicts of interest regarding the publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>8</Day><Hour>4</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36208052</ArticleId><ArticleId IdType="pmc">PMC9639628</ArticleId><ArticleId IdType="doi">10.1002/acn3.51667</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex&#x2010;linked recessive trait. Neurology. 1968;18:671&#x2010;680.</Citation><ArticleIdList><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Tanaka F, Adachi H, et&#xa0;al. Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol. 2012;99:246&#x2010;256.</Citation><ArticleIdList><ArticleId IdType="pubmed">22609045</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorar&#xf9; G, D'Ascenzo C, Polo A, et&#xa0;al. Spinal and bulbar muscular atrophy: skeletal muscle pathology in male patients and heterozygous females. J Neurol Sci. 2008;264:100&#x2010;105.</Citation><ArticleIdList><ArticleId IdType="pubmed">17854832</ArticleId></ArticleIdList></Reference><Reference><Citation>La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X&#x2010;linked spinal and bulbar muscular atrophy. Nature. 1991;352:77&#x2010;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">2062380</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z, Dadgar N, Albertelli M, et&#xa0;al. Androgen&#x2010;dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock&#x2010;in model. J Clin Invest. 2006;116:2663&#x2010;2672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1564432</ArticleId><ArticleId IdType="pubmed">16981011</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, Hashizume A, Yamada S, et&#xa0;al. Biomarker&#x2010;based analysis of preclinical progression in spinal and bulbar muscular atrophy. Neurology. 2018;90:e1501&#x2010;e1509.</Citation><ArticleIdList><ArticleId IdType="pubmed">29572281</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Banno H, Suzuki K, et&#xa0;al. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2010;9:875&#x2010;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">20691641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, et&#xa0;al. Long&#x2010;term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history&#x2010;controlled study. J Neurol Neurosurg Psychiatry. 2017;88:1026&#x2010;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">28780536</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki K, Nakanishi H, Nakamura T, et&#xa0;al. Myotonia&#x2010;like symptoms in a patient with spinal and bulbar muscular atrophy. Neuromuscul Disord. 2015;25:913&#x2010;915.</Citation><ArticleIdList><ArticleId IdType="pubmed">26363965</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannon SC. Channelopathies of skeletal muscle excitability. Compr Physiol. 2015;5:761&#x2010;790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4754081</ArticleId><ArticleId IdType="pubmed">25880512</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB. Effects of temperature on neuromuscular electrophysiology. Muscle Nerve. 2001;24:867&#x2010;882.</Citation><ArticleIdList><ArticleId IdType="pubmed">11410914</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb J, Cannon SC. Cold&#x2010;induced defects of sodium channel gating in atypical periodic paralysis plus myotonia. Neurology. 2008;70:755&#x2010;761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4094148</ArticleId><ArticleId IdType="pubmed">17898326</ArticleId></ArticleIdList></Reference><Reference><Citation>Straver DC, van Asseldonk JT, Notermans NC, Wokke JH, van den Berg LH, Franssen H. Cold paresis in multifocal motor neuropathy. J Neurol. 2011;258:212&#x2010;217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3036831</ArticleId><ArticleId IdType="pubmed">20803025</ArticleId></ArticleIdList></Reference><Reference><Citation>Tashiro K, Kikuchi S, Itoyama Y, et&#xa0;al. Nationwide survey of juvenile muscular atrophy of distal upper extremity (Hirayama disease) in Japan. Amyotroph Lateral Scler. 2006;7:38&#x2010;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">16546758</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson P, Ljunggren JG, Lins PE. Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group. Diabetes Care. 1997;20:1594&#x2010;1597.</Citation><ArticleIdList><ArticleId IdType="pubmed">9314641</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi JR, Bundy B, Statland J, et&#xa0;al. Non&#x2010;dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain. 2013;136:2189&#x2010;2200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3692030</ArticleId><ArticleId IdType="pubmed">23771340</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, Bundy BN, Wang Y, et&#xa0;al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA. 2012;308:1357&#x2010;1365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3564227</ArticleId><ArticleId IdType="pubmed">23032552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanai K, Kuwabara S, Arai K, Sung JY, Ogawara K, Hattori T. Muscle cramp in Machado&#x2010;Joseph disease: altered motor axonal excitability properties and mexiletine treatment. Brain. 2003;126:965&#x2010;973.</Citation><ArticleIdList><ArticleId IdType="pubmed">12615652</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashizume A, Katsuno M, Suzuki K, et&#xa0;al. A functional scale for spinal and bulbar muscular atrophy: cross&#x2010;sectional and longitudinal study. Neuromuscul Disord. 2015;25:554&#x2010;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5608513</ArticleId><ArticleId IdType="pubmed">25913211</ArticleId></ArticleIdList></Reference><Reference><Citation>Streib EW. AAEE minimonograph #27: differential diagnosis of myotonic syndromes. Muscle Nerve. 1987;10:603&#x2010;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">3309651</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier E, Viala K, Gervais H, et&#xa0;al. Cold extends electromyography distinction between ion channel mutations causing myotonia. Ann Neurol. 2006;60:356&#x2010;365.</Citation><ArticleIdList><ArticleId IdType="pubmed">16786525</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuntzer T, Michel P. Muscle membrane polarisation after provocative tests, and after cooling: the normal CMAP changes to be expected. Clin Neurophysiol. 2004;115:1457&#x2010;1463.</Citation><ArticleIdList><ArticleId IdType="pubmed">15134715</ArticleId></ArticleIdList></Reference><Reference><Citation>Michel P, Sternberg D, Jeannet PY, et&#xa0;al. Comparative efficacy of repetitive nerve stimulation, exercise, and cold in differentiating myotonic disorders. Muscle Nerve. 2007;36:643&#x2010;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">17654559</ArticleId></ArticleIdList></Reference><Reference><Citation>Hijikata Y, Katsuno M, Suzuki K, et&#xa0;al. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol. 2016;3:537&#x2010;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4931718</ArticleId><ArticleId IdType="pubmed">27386502</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilford JP. Fundamental Statistics in Psychology and Education. McGraw Hill; 1956.</Citation></Reference><Reference><Citation>Chan AW, Tetzlaff JM, Altman DG, et&#xa0;al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200&#x2010;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5114123</ArticleId><ArticleId IdType="pubmed">23295957</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan AW, Tetzlaff JM, G&#xf8;tzsche PC, et&#xa0;al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3541470</ArticleId><ArticleId IdType="pubmed">23303884</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz KF, Altman DG, Moher D, CONSORT Group . CONSORT Statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;2010(152):726&#x2010;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">20335313</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada S, Hashizume A, Hijikata Y, et&#xa0;al. Study protocol for the MEXiletine hydrochloride administration trial: a placebo&#x2010;controlled, randomised, double&#x2010;blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS). BMJ Open. 2018;8:e023041.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6144396</ArticleId><ArticleId IdType="pubmed">30206090</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Swash M. Nerve conduction studies in amyotrophic lateral sclerosis. Muscle Nerve. 2000;23:344&#x2010;352.</Citation><ArticleIdList><ArticleId IdType="pubmed">10679710</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. Translation, adaptation, and validation of the SF&#x2010;health survey for use in Japan. J Clin Epidemiol. 1998;51:1037&#x2010;1044.</Citation><ArticleIdList><ArticleId IdType="pubmed">9817121</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent KA, Carr AJ, Walburn J, Scott DL, Rose MR. Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL). Neurology. 2007;68:1051&#x2010;1057.</Citation><ArticleIdList><ArticleId IdType="pubmed">17389311</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, Wang Y, Richesson R, et&#xa0;al. An interactive voice response diary for patients with non&#x2010;dystrophic myotonia. Muscle Nerve. 2011;44:30&#x2010;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233757</ArticleId><ArticleId IdType="pubmed">21674518</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez&#x2010;Rhodes LE, Kokkinis AD, White MJ, et&#xa0;al. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo&#x2010;controlled trial. Lancet Neurol. 2011;10:140&#x2010;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3056353</ArticleId><ArticleId IdType="pubmed">21216197</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki K, Katsuno M, Banno H, et&#xa0;al. CAG repeat size correlates to electrophysiological motor and sensory phenotypes in SBMA. Brain. 2008;131:229&#x2010;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">18056738</ArticleId></ArticleIdList></Reference><Reference><Citation>Hama T, Hirayama M, Hara T, et&#xa0;al. Discrimination of spinal and bulbar muscular atrophy from amyotrophic lateral sclerosis using sensory nerve action potentials. Muscle Nerve. 2012;45:169&#x2010;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">22246870</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodgkin AL, Katz B. The effect of temperature on the electrical activity of the giant axon of the squid. J Physiol. 1949;109:240&#x2010;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1392577</ArticleId><ArticleId IdType="pubmed">15394322</ArticleId></ArticleIdList></Reference><Reference><Citation>Dlouh&#xe1; H, Donselaar Y, Teisinger J, Vyskocil F. Effect of temperature and ouabain on the Na+&#x2212;&#x2010;K+ activated membrane ATPase and electrogenic ionic pump of the golden hamster and mouse diaphragm. Physiol Bohemoslov. 1980;29:543&#x2010;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">6259677</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, Misawa S, Uzawa A, et&#xa0;al. Split hand and motor axonal hyperexcitability in spinal and bulbar muscular atrophy. J Neurol Neurosurg Psychiatry. 2020;91:1189&#x2010;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">32934003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawai S, Misawa S, Kanai K, et&#xa0;al. Altered axonal excitability properties in juvenile muscular atrophy of distal upper extremity (Hirayama disease). Clin Neurophysiol. 2011;122:205&#x2010;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">20624687</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamal GA, Weir AI, Hansen S, Ballantyne JP. Myotonic dystrophy. A reassessment by conventional and more recently introduced neurophysiological techniques. Brain. 1986;109:1279&#x2010;1296.</Citation><ArticleIdList><ArticleId IdType="pubmed">3790977</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermans MC, Faber CG, Vanhoutte EK, et&#xa0;al. Peripheral neuropathy in myotonic dystrophy type 1. J Peripher Nerv Syst. 2011;16:24&#x2010;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">21504499</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada S, Hashizume A, Hijikata Y, et&#xa0;al. Ratio of urinary N&#x2010;terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92:1072&#x2010;1079.</Citation><ArticleIdList><ArticleId IdType="pubmed">33737450</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida M, Sahashi K, Kondo N, et&#xa0;al. Src inhibition attenuates polyglutamine&#x2010;mediated neuromuscular degeneration in spinal and bulbar muscular atrophy. Nat Commun. 2019;10:4262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6753158</ArticleId><ArticleId IdType="pubmed">31537808</ArticleId></ArticleIdList></Reference><Reference><Citation>Suetterlin KJ, Bugiardini E, Kaski JP, et&#xa0;al. Long&#x2010;term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies. JAMA Neurol. 2015;72:1531&#x2010;1533.</Citation><ArticleIdList><ArticleId IdType="pubmed">26658970</ArticleId></ArticleIdList></Reference><Reference><Citation>Heatwole C, Luebbe E, Rosero S, et&#xa0;al. Mexiletine in myotonic dystrophy type 1: a randomized, double&#x2010;blind, placebo&#x2010;controlled trial. Neurology. 2021;96:e228&#x2010;e240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7905778</ArticleId><ArticleId IdType="pubmed">33046619</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganelli F, Iodice V, Provitera V, et&#xa0;al. Small&#x2010;fiber involvement in spinobulbar muscular atrophy (Kennedy's disease). Muscle Nerve. 2007;36:816&#x2010;820.</Citation><ArticleIdList><ArticleId IdType="pubmed">17691102</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat PF, Bernard E, Corcia P, et&#xa0;al. The French national protocol for Kennedy's disease (SBMA): consensus diagnostic and management recommendations. Orphanet J Rare Dis. 2020;15:90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149864</ArticleId><ArticleId IdType="pubmed">32276665</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki A, Katsuno M, Suzuki K, et&#xa0;al. Brugada syndrome in spinal and bulbar muscular atrophy. Neurology. 2014;82:1813&#x2010;1821.</Citation><ArticleIdList><ArticleId IdType="pubmed">24759840</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>